Authors
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin, Eric Winquist, Gloria E Sarto, Judy E Garber, Carol J Fabian, Pascal Pujol, Elizabeth Maunsell, Patricia Farmer, Karen A Gelmon, Dongsheng Tu, Harriet Richardson
Publication date
2011/6/23
Journal
New England Journal of Medicine
Volume
364
Issue
25
Pages
2381-2391
Publisher
Massachusetts Medical Society
Description
Background
Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.
Methods
In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors: 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.
Results
A total of 4560 women for whom the median age was 62.5 …
Total citations
Scholar articles
PE Goss, JN Ingle, JE Alés-Martínez, AM Cheung… - New England Journal of Medicine, 2011